Financial Reports Latest Updates Industry Maps Economic Calendar

Century Therapeutics, Inc. (IPSC) Annual Reports

Q: Where can I read Century Therapeutics, Inc. (IPSC) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Century Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under Biological Products, (No Diagnostic Substances) (SIC 2836). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1850119 →

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Operating income	$-36.5M	$-34.7M	-5.4%
Net income	$-34.5M	$-32.5M	-6.2%
EPS (diluted)	$-0.17	$-0.38	+55.3%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 0 mn Net income -34.5 mn

Show table：Income statement

Item	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	—	—	—	—	—	1.06	1.40	2.22	0.52	1.72	0.1	0.15	0.27	0.86	0.77	0.79	4.17	109	0	0	0	—	—
Operating income	—	-15.5	-13.1	-15.3	-18.1	-23.0	-25.8	-28.0	-37.4	-31.4	-31.7	-33.3	-32.1	-35.1	-35.6	-43.8	-31.3	-34.8	-34.8	-37.3	74.2	-34.7	-36.1	-20.6	-23.7	-36.5
Net income	-9.67	-15.3	-13.1	-15.5	-18.4	-23.3	-26.0	-28.2	-37.5	-31.0	-30.8	-31.7	-31.3	-33.3	-32.7	-39.4	-28.1	-31.2	-31.2	-36.1	76.6	-32.5	-34.4	-19.2	-21.6	-34.5

Balance sheet

Quarterly · In mn (USD)

Total assets 287 mn Total liabilities 54.7 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	78.8	—	403	300	228	365	384	362	320	256	161	174	177	200	203	206	194	170	160	138	121	139	125
Total assets	—	—	—	107	—	496	470	437	550	533	512	487	456	417	398	361	349	416	389	353	316	285	245	224	327	287
Current liabilities	—	—	—	12.1	—	21.2	19.9	15.7	22.0	21.6	26.9	29.8	27.7	19.2	20.4	17.9	16.1	19.2	19.8	130	14.5	14.9	22.0	20.2	13.6	15.1
Total liabilities	—	—	—	33.4	—	48.0	46.7	41.1	164	175	182	184	179	170	178	176	171	194	193	192	75.2	74.8	68.4	64.8	61.8	54.7
Equity	-101	-116	-129	-106	-91.6	448	423	396	387	358	330	303	277	248	219	185	178	222	196	161	240	210	176	159	265	232

Cash flow

Quarterly · In mn (USD)

Operating -19.8 mn Investing 17.8 mn Financing 0.31 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	—	-18.8	-9.22	-13.2	-22.2	-18.5	-24.0	-24.4	86.8	-25.6	-24.2	-22.9	-29.2	-19.3	-13.7	-26.2	-30.3	-27.3	-28.3	-24.2	-34.6	-27.6	-25.6	-16.1	-25.3	-19.8
Investing	—	-2.45	0.48	-20.8	-119	-11.7	-147	-20.6	-44.0	12.5	22.7	-4.27	31.3	6.97	4.22	18.6	11.5	-33.9	39.2	30.6	27.9	32.5	24.7	22.4	-113	17.8
Financing	—	-0.01	9.60	38.1	193	225	-0.47	0.11	26.9	0.05	0.14	0.1	0.45	-10.1	0.3	-0.36	18.2	56.7	0.27	-0.6	0.12	0	0	0.05	127	0.31
Cash at period end	—	22.8	23.6	27.2	80.0	272	101	56.5	126	113	111	84.3	86.8	64.4	55.3	47.3	46.8	41.5	52.6	58.4	51.9	56.9	55.5	61.9	51.0	49.6

Profitability

Quarterly · %

Operating margin 68.0% Net margin 70.1%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	—	—	—	—	-3538.4%	-2245.8%	-1427.1%	-6392.7%	-1865.2%	-35431.3%	-24071.6%	-16329.1%	-3661.9%	-4507.8%	-4398.1%	-893.5%	68.0%	—	—	—	—	—
Net margin	—	—	—	—	—	—	—	—	-3545.7%	-2219.8%	-1382.6%	-6081.0%	-1817.7%	-33627.3%	-22108.1%	-14700.8%	-3282.1%	-4047.6%	-3947.7%	-864.4%	70.1%	—	—	—	—	—

Returns & leverage

Quarterly · %

ROE -49.6% ROA -38.4% Debt ratio 19.1%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	-42.4%	-56.6%	-66.1%	-77.9%	-30.5%	-33.8%	-37.5%	-37.6%	-41.9%	-46.9%	-56.1%	-58.7%	-56.0%	-62.6%	-73.1%	-10.5%	-10.8%	-14.2%	-6.0%	-42.7%	-49.6%
ROA	—	—	—	-50.2%	—	-14.2%	-17.7%	-35.2%	-20.9%	-23.9%	-26.0%	-28.3%	-24.8%	-26.7%	-28.4%	-32.3%	-33.2%	-31.5%	-33.0%	-35.5%	-6.6%	-6.6%	-8.4%	-3.3%	-33.6%	-38.4%
Debt ratio	—	—	—	31.3%	—	9.7%	9.9%	9.4%	29.7%	32.8%	35.5%	37.8%	39.3%	40.6%	44.9%	48.8%	49.0%	46.7%	49.6%	54.3%	23.8%	26.3%	27.9%	28.9%	18.9%	19.1%

EPS

Quarterly · US$

EPS US$-0.17

Show table：EPS

Item	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	-1.75	-2.08	-2.39	-1.93	-0.48	-0.24	-0.66	-0.54	-0.53	-0.55	-0.53	-0.56	-0.55	-0.62	-0.45	-0.38	-0.37	-0.43	0.89	-0.38	-0.40	-0.25	-0.11	-0.17

Revenue & profit

Year-to-date · In mn (USD)

Revenue 109 mn Net income -56.2 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 287 mn Total liabilities 54.7 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -45.1 mn Investing -94.8 mn Financing 127 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -15.8% Net margin -8.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -49.6% ROA -38.4% Debt ratio 19.1%

EPS

Year-to-date · US$

EPS US$-0.28

Revenue & profit

Annual · In mn (USD)

Revenue 109 mn Net income -9.57 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2020	2021	2022	2023	2024	2025
Revenue	—	—	5.20	2.24	6.59	109
Operating income	—	-94.9	-134	-147	-138	-17.3
Net income	-53.6	-95.8	-131	-137	-127	-9.57

Balance sheet

Annual · In mn (USD)

Total assets 224 mn Total liabilities 64.8 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2020	2021	2022	2023	2024	2025
Current assets	78.8	228	320	177	194	121
Total assets	107	437	487	361	353	224
Current liabilities	12.1	15.7	29.8	17.9	130	20.2
Total liabilities	33.4	41.1	184	176	192	64.8
Equity	-106	396	303	185	161	159

Cash flow

Annual · In mn (USD)

Operating -104 mn Investing 108 mn Financing 0.17 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2020	2021	2022	2023	2024	2025
Operating	—	-89.0	14.1	-88.3	-110	-104
Investing	—	-298	-13.1	61.1	47.5	108
Financing	—	418	27.2	-9.72	74.6	0.17
Cash at period end	27.2	56.5	84.3	47.3	58.4	61.9

Profitability

Annual · %

Operating margin -15.8% Net margin -8.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2020	2021	2022	2023	2024	2025
Operating margin	—	—	-2574.2%	-6556.9%	-2096.2%	-15.8%
Net margin	—	—	-2518.4%	-6115.1%	-1920.6%	-8.8%

Returns & leverage

Annual · %

ROE -6.0% ROA -3.3% Debt ratio 28.9%

Show table：Returns & leverage

Item	2020	2021	2022	2023	2024	2025
ROE	—	-66.1%	-37.5%	-56.1%	-73.1%	-6.0%
ROA	-50.2%	-35.2%	-28.3%	-32.3%	-35.5%	-3.3%
Debt ratio	31.3%	9.4%	37.8%	48.8%	54.3%	28.9%

EPS

Annual · US$

EPS US$-0.14

Show table：EPS

Item	2020	2021	2022	2023	2024	2025
EPS（US$）	—	-5.04	-2.28	-2.26	-1.63	-0.14

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Century Therapeutics, Inc. (IPSC) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.